RxSight (RXST) Scheduled to Post Earnings on Monday

RxSight (NASDAQ:RXST) is set to release its earnings data after the market closes on Monday, May 6th. Analysts expect RxSight to post earnings of ($0.17) per share for the quarter. RxSight has set its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

RxSight (NASDAQ:RXST) last issued its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. The firm had revenue of $28.58 million during the quarter, compared to analyst estimates of $28.60 million. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RxSight Stock Up 3.4 %

Shares of NASDAQ:RXST opened at $61.68 on Friday. The firm has a market capitalization of $2.29 billion, a PE ratio of -43.13 and a beta of 1.21. RxSight has a twelve month low of $18.09 and a twelve month high of $61.85. The company has a 50-day moving average price of $52.59 and a two-hundred day moving average price of $42.56.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of RxSight in a research report on Thursday, April 11th. Oppenheimer upped their target price on shares of RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Stifel Nicolaus raised their price target on shares of RxSight from $54.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Finally, JPMorgan Chase & Co. boosted their price target on shares of RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $49.63.

Insiders Place Their Bets

In other news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $52.69, for a total transaction of $526,900.00. Following the sale, the chief financial officer now owns 13,938 shares in the company, valued at approximately $734,393.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Bakker Juliet Tammenoms bought 4,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was acquired at an average price of $51.29 per share, with a total value of $205,160.00. Following the completion of the purchase, the director now directly owns 29,840 shares in the company, valued at $1,530,493.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total transaction of $526,900.00. Following the transaction, the chief financial officer now directly owns 13,938 shares in the company, valued at $734,393.22. The disclosure for this sale can be found here. Insiders sold a total of 59,490 shares of company stock valued at $3,043,578 in the last quarter. Corporate insiders own 21.13% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.